향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2162개
향후 6개월 catalyst 5건 기준 in-memory 집계 (추가 DB 조회 없음)
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 7월 | Darzalex (daratumumab)Antibody · CD38 | Phase 3 | Active, not recruiting | overall survival | 신뢰 높음 | NCT03836014 |
| 2026년 7월 | Keytruda (pembrolizumab)Antibody · PD-1 | Phase 1, Phase 2 | Active, not recruiting | Phase I: Maximum Tolerated Dose (MTD) | 신뢰 높음 | NCT02638090 |
| 2026년 7월 | Humira (adalimumab)Antibody · TNF-α | Phase 3 | Active, not recruiting | Percentage of Participants Achieving Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) <= 3.2; Number of Participants with Adverse Events | 신뢰 높음 | NCT05814627 |
| 2026년 7월 | Enhertu (trastuzumab deruxtecan)ADC · HER2 | Phase 1 | Active, not recruiting | Incidence of dose limiting toxicities in Phase 1a monotherapy; Incidence of adverse events in Phase 1a monotherapy; incidence of laboratory abnormalities in Phase 1a monotherapy; incidence of ECG abnormalities in Phase 1a monotherapy; incidence of dose limiting toxicities in Phase 1a combination with fam-trastuzumab deruxtecan (T-DXd); Incidence of adverse events in Phase 1a combination with T-DXd; incidence of laboratory abnormalities in Phase 1a combination with T-DXd; incidence of ECG abnormalities in Phase 1a combination with T-DXd; incidence of dose limiting toxicities in Phase 1a combination with trastuzumab emantasine (T-DM1); Incidence of adverse events in Phase 1a combination with T-DM1; incidence of laboratory abnormalities in Phase 1a combination with T-DM1; incidence of ECG abnormalities in Phase 1a combination with T-DM1; Incidence of adverse events in Phase 1b monotherapy; incidence of laboratory abnormalities in Phase 1b monotherapy; incidence of ECG abnormalities in Phase 1b monotherapy | 신뢰 높음 | NCT05650879 |
| 2026년 7월 | Ebglyss (lebrikizumab)Antibody · IL-13 | Phase 3 | Active, not recruiting | Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥2-point Improvement from Baseline | 신뢰 높음 | NCT06921759 |
향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS
큐레이션·FDA·임상 3건 이상 프로그램 2162개
향후 6개월 catalyst 5건 기준 in-memory 집계 (추가 DB 조회 없음)
| 완료 예정 | 프로그램 | Phase | Status | Endpoint | 신뢰도 | NCT |
|---|---|---|---|---|---|---|
| 2026년 7월 | Darzalex (daratumumab)Antibody · CD38 | Phase 3 | Active, not recruiting | overall survival | 신뢰 높음 | NCT03836014 |
| 2026년 7월 | Keytruda (pembrolizumab)Antibody · PD-1 | Phase 1, Phase 2 | Active, not recruiting | Phase I: Maximum Tolerated Dose (MTD) | 신뢰 높음 | NCT02638090 |
| 2026년 7월 | Humira (adalimumab)Antibody · TNF-α | Phase 3 | Active, not recruiting | Percentage of Participants Achieving Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) <= 3.2; Number of Participants with Adverse Events | 신뢰 높음 | NCT05814627 |
| 2026년 7월 | Enhertu (trastuzumab deruxtecan)ADC · HER2 | Phase 1 | Active, not recruiting | Incidence of dose limiting toxicities in Phase 1a monotherapy; Incidence of adverse events in Phase 1a monotherapy; incidence of laboratory abnormalities in Phase 1a monotherapy; incidence of ECG abnormalities in Phase 1a monotherapy; incidence of dose limiting toxicities in Phase 1a combination with fam-trastuzumab deruxtecan (T-DXd); Incidence of adverse events in Phase 1a combination with T-DXd; incidence of laboratory abnormalities in Phase 1a combination with T-DXd; incidence of ECG abnormalities in Phase 1a combination with T-DXd; incidence of dose limiting toxicities in Phase 1a combination with trastuzumab emantasine (T-DM1); Incidence of adverse events in Phase 1a combination with T-DM1; incidence of laboratory abnormalities in Phase 1a combination with T-DM1; incidence of ECG abnormalities in Phase 1a combination with T-DM1; Incidence of adverse events in Phase 1b monotherapy; incidence of laboratory abnormalities in Phase 1b monotherapy; incidence of ECG abnormalities in Phase 1b monotherapy | 신뢰 높음 | NCT05650879 |
| 2026년 7월 | Ebglyss (lebrikizumab)Antibody · IL-13 | Phase 3 | Active, not recruiting | Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥2-point Improvement from Baseline | 신뢰 높음 | NCT06921759 |